Overview |
bs-5486R |
ERK5 (Ser731+Thr733) Polyclonal Antibody |
WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
Recognizes Ser721+Thr723 in mice and rats |
Human |
Mouse, Rat, Dog, Cow, Rabbit |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic phosphopeptide derived from human ERK5 around the phosphorylation sites of Ser731+Thr733 |
Ser731+Thr733 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
5598 |
Q13164 |
Cytoplasm, Nucleus |
BMK1; ERK4; ERK5; PRKM7; Mitogen-activated protein kinase 7; MAP kinase 7; MAPK 7; Big MAP kinase 1; BMK-1; Extracellular signal-regulated kinase 5; ERK-5; MAPK7 |
Plays a role in various cellular processes such as proliferation, differentiation and cell survival. The upstream activator of MAPK7 is the MAPK kinase MAP2K5. Upon activation, it translocates to the nucleus and phosphorylates various downstream targets including MEF2C. EGF activates MAPK7 through a Ras-independent and MAP2K5-dependent pathway. May have a role in muscle cell differentiation. May be important for endothelial function and maintenance of blood vessel integrity. MAP2K5 and MAPK7 interact specifically with one another and not with MEK1/ERK1 or MEK2/ERK2 pathways. Phosphorylates SGK1 at Ser-78 and this is required for growth factor-induced cell cycle progression. Involved in the regulation of p53/TP53 by disrupting the PML-MDM2 interaction. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |